Navigation Links
Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
Date:2/5/2008

NEW YORK, Feb. 5 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will be presenting at the following upcoming Investor Conferences:

Thursday, February 7th, 2008 - 10:20 AM ET:

Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference
Grand Hyatt Hotel

New York City

Monday, February 11, 2008 - 12:30 PM ET:

BIO CEO & Investor Conference

Waldorf=Astoria Hotel

New York City

Each of Mr. Weiss' presentations will be webcast live and may be accessed from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of each presentation webcast will be available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM) (sulodexide oral gelcap), previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase 3 and Phase 4 clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, iron- based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
3. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
4. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
5. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
6. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
7. Nabi Biopharmaceuticals to Present at the BMO Capital Markets Focus on Healthcare Conference
8. China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals Stockholders Approve Asset Sale
10. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
11. RiskMetrics Group (ISS) and Glass Lewis & Co. Support Nabi Biopharmaceuticals Proposed Asset Sale
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2013 was a banner year of continued ... saw continued independent research led by the team at ... $1 million grant from the Susanne Marcus Collins Foundation, ... peer reviewed journal, Amy Grant highlighted Brainwave Optimization® in ...
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
(Date:1/14/2014)... Diego, CA (PRWEB) January 14, 2014 ... on the products of cells grown under simulated embryonic ... international license agreement with Suneva Medical, Inc. for physician-dispensed ... (CCM). , This agreement is an amendment ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... ("CTI") (Nasdaq and MTA: CTIC) announced today that it has been ... posted by Russell Investments on June 29, 2009 on ... and global equity indexes on an annual basis. , ... largest U.S. stocks as of the last trading day of May, ...
... Corp. (Nasdaq: BSTC ), a biopharmaceutical company developing ... added to the Russell 3000 and Russell 2000 Indexes effective ... 2009. The Russell family of U.S. indexes is reconstituted annually ... investable U.S. equity market. , , The Russell 3000 ...
... Micromet, Inc. (Nasdaq: MITI ), a ... of cancer, inflammation and autoimmune diseases, today announced that ... part of the annual reconstitution of the Russell indexes, ... "Investors recognize the Russell 3000 as an established benchmark ...
Cached Biology Technology:Cell Therapeutics Added to Russell 3000(R), Russell 2000(R) and Russell Global(R) Indexes 2Cell Therapeutics Added to Russell 3000(R), Russell 2000(R) and Russell Global(R) Indexes 3BioSpecifics Technologies Corp. Added to Russell 3000 and Russell 2000 Indexes 2Micromet Added to Russell 3000 Index 2Micromet Added to Russell 3000 Index 3Micromet Added to Russell 3000 Index 4
(Date:7/9/2014)... fungal pathogens pose a greater threat to biodiversity ... of amphibians, bats, corals, bees and snakes. New ... in the prestigious journal Nature reveals ... to a deadly chytrid fungus implicated in global ... important because it is the basis of vaccination ...
(Date:7/9/2014)... Guelph scientist that involved fitting bumblebees with tiny ... neonicotinoid pesticide hampers bees, ability to forage for ... professor in Guelph,s School of Environmental Sciences, and ... July 9 in the British Ecological Society,s journal ... how long-term pesticide exposure affects individual bees, day-to-day ...
(Date:7/9/2014)... fever but often can be defeated with antibiotics and ... beat. Now, scientists have built a new weapon against such ... the journal ACS Applied Materials & Interfaces , their ... of them than medicine alone. , David Leong, Jianping Xie ... wait, undetectable in the human body or in places that ...
Breaking Biology News(10 mins):USF study: Amphibians can acquire resistance to deadly fungus 2Bee foraging chronically impaired by pesticide exposure: Study 2
... why a tuberculosis vaccine is not as effective for some ... not work as well for some as they do for ... issue of the Journal of Leukocyte Biology ( ... common environmental bacterium found in soil and water, can decrease ...
... State University have solved a long-standing conundrum about ... way into limestone, sand grains, mussel shells, coral ... According to the lead investigator, ASU professor ... what is "at the heart of an erosive ...
... New Rochelle, NY, November 30, 2010Access to quality reproductive ... aspect of a woman,s human rights, freedom, equity, and ... on Global Women,s Reproductive Health in the current issue ... by Mary Ann Liebert, Inc., explores the compelling medical, ...
Cached Biology News:Blame the environment: Why vaccines may be ineffective for some people 2Mystery dissolves with calcium pump discovery 2Mystery dissolves with calcium pump discovery 3Ensuring the rights of women worldwide to reproductive health care 2
PHOTOMAN DIRECT COPY CAMERA, 1 EA. Category: Nucleid Acid Detection Systems....
Recombinant Human Erythropoietin (Tissue Culture Grade)...
One-step, microplate or cuvet, colorimetric, detection range 0.78 ug/dL to 65 ug/dL Zn in serum, plasma, urine, saliva etc. Procedure: 10 min....
Human PDGF R beta MAb (Clone # PR7212)...
Biology Products: